

**Minutes of the December 9, 2016
Pharmacy & Therapeutics (P&T) Committee Meeting
South Dakota Department of Social Services, Division of Medical Services**

Members Present

Dana Darger, Mikal Holland, Bill Ladwig, Michelle Baack, Kelley Oehlke, Richard Holm, Lenny Petrik, James Engelbrecht, Timothy Soundy

DSS Staff Present

Mike Jockheck

Administrative Business

The meeting was called to order by Darger at 1:05 P.M. The minutes of the September meeting were presented. Ladwig made a motion to approve, Baack seconded the motion. The motion was approved unanimously.

Prior Authorization Update (PA) and Statistics

The committee reviewed the PA activity for September 2016. There were a total of 3,129 Pas processed in the month of September, with 99.74% of those requests responded to in less than eight hours. There were 2,422 requests (77%) received electronically and 707 requests (23%) received by fax. Baack noted a possible increase in the number of maximum units override requests.

Analysis of the Top 15 Therapeutic Classes and Drug Spend

The committee reviewed the top 15 therapeutic classes by total cost of claims from 7/1/2016 – 9/30/2016. The top five classes were antipsychotic agents, insulins, respiratory and CNS stimulants, amphetamines, and anticonvulsants, misc. The top 15 therapeutic classes make up 39.59% of total claims. The committee also reviewed the top 50 drugs based on total claims cost and number of claims. The top 50 drugs by claims cost make up 14.79% of total claims. Darger questioned the inclusion of some physician administered drugs in the top 50.

Patent Expiration Review

The committee reviewed the anticipated availability of first-time generics. Darger asked if a biosimilar presentation with an emphasis on insulins would be helpful at the next meeting. Possible presenters will be researched. Holland recommended that committee members review a Frequently Asked Questions document produced by Prescribers Letter.

Methadone Second Review

Methadone was reviewed at the September meeting. At that time the committee asked that a methadone PA form be developed and brought back to the December meeting for review. Baack motioned to add pediatric and adult abstinence syndrome to the list of covered diagnosis. Oehlke seconded. The motion was unanimously approved.

Jockheck gave an overview for a proposed opioid utilization plan. Ladwig suggested the Methadone PA should be clearer. The form will be brought back to the committee for review at the March meeting.

Opioid Strategies for Management Review

At the September meeting the state asked the committee to provide insight on ways to manage opioid utilization. The committee asked that more information be provided at the December meeting pertaining to a Lock-In Program as well as morphine equivalent dosing. That information was presented for the Committees review. Ladwig suggested pain contracts. Darger suggested a review of the South Dakota Board of Medicine guidelines. Holland mentioned the South Dakota Legislature may also be looking at Legislation in this area. Baack mentioned that all Sanford affiliated prescribers are required to create an account with the South Dakota Prescription Drug Monitoring Program. Holland suggested that recipients also be included in any Lock-In related communications. Ladwig motioned to create a Lock-In program. Baack seconded. The motion passed unanimously. Holland moved to create morphine equivalent dosing limits. Ladwig Seconded. The motion passed unanimously. There was no public comment.

Zinbryta Second Review

At the September meeting the committee requested a PA form be developed and presented at the December meeting for review. There was no public comment. Baack motioned to approve. Oehlke seconded. The motion passed unanimously.

Byvalson Second Review

At the September meeting the committee requested a PA form be developed and presented at the December meeting for review. There was no public comment. Engelbrecht motioned to approve. Holm seconded. The motion passed unanimously.

Onfi Review

PA requests for off-label use of Onfi have been increasing. The current Onfi PA form and utilization were presented for updated Committee recommendation. There was no public comment. Baack motioned to add language covering Onfi for intractable, treatment resistant seizure disorders, to remove the age restriction, and to require it to

be prescribed by a neurologist. Engelbrecht seconded. The motion passed unanimously.

Specialty Medication Review

Engelbrecht suggested a review of specialty medications may be pertinent. Utilization of medications over \$5,000 was presented to the Committee. Engelbrecht gave an overview of the issues pertaining to specialty medications. Darger recommended the removal of physician administered drugs from pharmacy benefit coverage. Petrik noted an apparent error in the per prescription cost of Harvoni. Holm motioned that further study be done regarding how other Medicaid agencies control specialty medications. There was no public comment.

Over-the-counter (OTC) Iron

The State requested the committee's insight whether OTC iron should be a covered product. There was no public comment. Holm requested information regarding what other State Medicaid's do with OTC Iron.

Orfadin Review

No action was taken. There was no public comment.

Xiidra Review

No action was taken. There was no public comment.

Nuplazid Review

Nuplazid information was presented for review. There was no public comment. Engelbrech motioned a PA form be developed for the approved indications and which requires a neurologist or psychiatrist consult before being approved. Ladwig seconded. The motion passed unanimously.

Misc.

Jockheck gave the Committee an update regarding the new Pharmacy Point of Sale Project.

The next meetings are scheduled for 3/31/2017, and 6/16/2017. Holm motioned to adjourn. Holland Seconded. The meeting adjourned at 2:19 P.M.